$1.64▴ 1.86%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-193.40MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Moderatedebt to assets
Watch
Elevated leverage worth keeping an eye on.
More coming: dilution / share-count creep.
✦ The read
Neumora Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Elevated leverage worth keeping an eye on.
Key numbers
Valuation
EPS (TTM)$-1.33
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$0.00
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.